VanEck Pharmaceutical ETF
PPH
50 hedge funds and large institutions have $105M invested in VanEck Pharmaceutical ETF in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 11 closing their positions.
7% more capital invested
Capital invested by funds: $98.3M → $105M (+$6.57M)
0.61% more ownership
Funds ownership: 37.51% → 38.11% (+0.61%)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2% less funds holding
Funds holding: 51 → 50 (-1)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$10.9M |
| 2 |
Goldman Sachs
New York
|
+$10.8M |
| 3 |
CCT
Country Club Trust
Kansas City,
Missouri
|
+$677K |
| 4 |
WI
Wintrust Investments
Chicago,
Illinois
|
+$317K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$307K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$13.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2M |
| 3 |
CC
Colrain Capital
Boston,
Massachusetts
|
-$1.25M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$959K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$938K |
PPH Hedge Fund Activity: Q1 2017 in Review
50 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2017, worth a combined $105M — up 6.7% from $98.3M a quarter earlier.
Fund positioning in PPH was balanced in Q1 2017: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 14 trimmed.
The largest buyer was Citigroup, adding an estimated $10.9M. The largest seller was JP Morgan Chase, cutting an estimated $13.6M.
- 50 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2017, down from 51 in Q4 2016.
- Funds reported $105M of VanEck Pharmaceutical ETF stock for Q1 2017, up 6.7% quarter-over-quarter.
- 11 funds opened new VanEck Pharmaceutical ETF positions in Q1 2017 and 11 closed out, a net change of 0 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2017 was Citigroup, an estimated $10.9M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2017 was JP Morgan Chase, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2017.